NCT06200233View on ClinicalTrials.gov

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

December 1, 2026

Conditions
Thymic Epithelial Tumor
Interventions
DRUG

Rivoceranib

700mg once daily

Trial Locations (1)

135-710

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT06200233 - Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor | Biotech Hunter | Biotech Hunter